We have located links that may give you full text access.
Mitochondrial Dysfunction: Metabolic Drivers of Pulmonary Hypertension.
Antioxidants & Redox Signaling 2019 January 4
Pulmonary hypertension (PH) is a progressive disease characterized by pulmonary vascular remodeling and lung vasculopathy. The disease displays progressive dyspnea, pulmonary artery uncoupling, and right ventricular (RV) dysfunction. The molecular events that promote the development of pulmonary hypertension are complex and incompletely understood. Metabolic impairment has been proposed to contribute to the pathophysiology of PH with evidence for mitochondrial dysfunction involving the electron transport chain proteins, antioxidant enzymes, apoptosis regulators and mitochondrial quality control. It is vital to characterize the mechanisms by which mitochondrial dysfunction contribute to PH pathogenesis. This review focus on the currently available publications that supports mitochondrial mechanisms in PH pathophysiology. Further studies of these metabolic mitochondrial alterations in PH could be viable targets of therapeutic intervention.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app